Get the Message
Conventional prophylactic vaccines have had a huge impact on the treatment and prevention of many diseases, but mRNA-based approaches – utilising these molecules’ highly versatile, non-toxic and temperature-insensitive characteristics – may be the way forward, says CureVac’s Ingmar Hoerr.
Ingmar Hoerr, CureVac (December 2014)
Keywords: Prophylactic vaccines, Cancer immunotherapy, Messenger RNA,
Good Manufacturing, Practice, Toll-like receptors, Humoral and cellular responses